Hear from us 1 December 2025 Orphalan, a global pharmaceutical company specializing in the development and commercialization of orphan drugs, announces the acquisition of Orphelia Pharma, a French pharmaceutical company dedicated to rare and serious pediatric diseases in neurology and oncology. Read More > 12 March 2025 Orphelia Pharma provides update on KIZFIZO® regulatory submission with the European Medicines Agency Read More > 18 November 2024 Orphelia Pharma provides update on the regulatory submission of KIZFIZO® with the European Medicines Agency Read More > 11 June 2024 ORPHELIA Pharma to collaborate with Oscar Lambret clinical center to study KIZFIZO®, the first pediatric drinkable formulation of temozolomide, for the treatment of refractory or relapsed nephroblastoma (Wilms tumor) Read More > 22 May 2024 ORPHELIA Pharma and University of Birmingham strengthen their collaboration to support the registration of KIZFIZO® Read More > 18 April 2024 Orphelia Pharma secures European patent covering KIGABEQ®, the first pediatric formulation of vigabatrin Read More >
